HC Wainwright

HC Wainwright initiated coverage on Flex Pharma, Inc. (NASDAQ: FLKS) with a Buy rating. The target price for Flex Pharma is set to $40. Flex Pharma shares closed at $19.46 yesterday.

Analysts at HC Wainwright initiated coverage on Redhill Biopharma Ltd. (NASDAQ: RDHL) with a Buy rating. The target price for Redhill Biopharma is set to $23. Redhill Biopharma shares have dropped 0.29% over the past 52 weeks, while the S&P 500 index has surged 11.47% in the same period....

Analysts at HC Wainwright initiated coverage on Finjan Holdings (NASDAQ: FNJN) with a Buy rating. The target price for Finjan Holdings is set to $5. Finjan shares have dropped 55.43% over the past 52 weeks, while the S&P 500 index has gained 17.64% in the same period. Finjan Holdings' shares...

Vertex Pharmaceuticals (NASDAQ: VRTX) reported earnings after the bell on Tuesday, July 29, that beat consensus estimates. Despite the beat, the stock declined in Wednesday's trading action by 3.73 percent. Credit Suisse reiterated a Neutral rating, $94 price target: “VRTX reported non-GAAP EPS...

HC Wainwright cut its rating on Vertex Pharmaceuticals (NASDAQ: VRTX) to Neutral after the stock rallied nearly 50 percent Tuesday. Analyst Andrew Fein started, “VRTX shares are finally appropriately valued.” Regarding VX-809’s commercialization, Fein shares his concerns:...